Adult Dosing

Treatment of bacterial conjunctivitis

• 1 gtt bid x 2 days, 8-12 hrs apart, then 1 gtt Daily for next 5 days

Pediatric Dosing

• Note: Safety and effectiveness in pediatric patients < 1 year of age have not been established

Treatment of bacterial conjunctivitis

• Child 1 yrs: 1 gtt bid x 2 days, 8-12 hrs apart, then 1 gtt Daily for next 5 days

• Azithromycin ophthalmic, a macrolide antibiotic, is indicated for bacterial conjunctivitis, caused by susceptible isolates of the following microorganisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae

• Hypersensitivity to any of the ingredients of the product
• Contact lens use

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• This formulation is indicated for topical ophthalmic use only
• Keep a space of 8-12 hrs for the initial bid doses
• Prolonged use may result in growth of resistant organisms
• In cases of bacterial conjunctivitis, contact lenses should not be worn
• Anaphylaxis and hypersensitivity have been reported with systemic use

Supplemental Patient Information

• Patients should be advised to avoid contaminating the applicator tip by allowing it to touch the eye, fingers or other sources
• Patients should be directed to discontinue use and contact a physician if any signs of an allergic reaction occur
• Advise patients not to wear contact lenses if they have signs/symptoms of bacterial conjunctivitis

AzaSite interacts with :

	Afinitor
	Apixaban
	Astagraf XL
	Betrixaban (Bevyxxa)
	Cyclosporine
	Dabigatran
	Edoxaban
	Eliquis
	Everolimus
	Gengraf
	Hecoria
	Lanoxicaps
	Lanoxin
	Lanoxin pediatric
	Neoral
	Pradaxa
	Prograf
	Protopic
	Rapamune
	Restasis
	Rivaroxaban
	Sandimmune
	Savaysa
	Sirolimus
	Tacrolimus
	Xarelto

Pregnancy Category:B

Breastfeeding: Safety Unknown; however systemic absorption is minimal; so may have minimal excretion to breast milk. The drug would not be expected to cause any adverse effects in breastfed infants. Manufacturer advises caution.

• EENT: Eye irritation, burning, stinging, corneal erosion, dry eye, ocular discharge, punctate keratitis
• DERM: Contact dermatitis
• GI: Dysgeusia
• RESP: Sinusitis, nasal congestion
• MISC: Superinfection
• HYPERSENSITIVITY: Hypersensitivity reaction, anaphylaxis

• Macrolide antibiotic; binds to 50S ribosomal subunit of susceptible microorganisms and interferes with microbial protein synthesis
• Topically applied and minimally absorbed
• Metabolized by liver; CYP450: Unknown
• Renally excreted: 6% unchanged; primarily in bile (> 50% unchanged)
• Half-life: 68 hrs

US Trade Name(s)

• AzaSite

US Availability

AzaSite

• OPTH SOLN: 1% (2.5 mL)

Canadian Trade Name(s)

• AzaSite

Canadian Availability

AzaSite

• OPTH SOLN: 1% (2.5 mL)

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Antibiotics

Macrolides

Infectious Disease

Antibiotics

Macrolides

Antimicrobials

Ophthalmic Anti-infectives

Infectious Disease

Ophthalmic Anti-infectives

Ophthalmic

Ophthalmic Anti-infectives

Pricing data from www.DrugStore.com in U.S.A.

• AzaSite 1 % SOLN [Bottle] (INSPIRE PHARMACEUTICALS)
  INC. % = $2.5
  % = $7.5

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.